Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF. Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(6): 2350-2361 [PMID: 38994143 DOI: 10.4251/wjgo.v16.i6.2350]
Corresponding Author of This Article
Deng-Fu Yao, MD, PhD, Professor, Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, No. 20 West Temple Road, Nantong 226001, Jiangsu Province, China. yaodf@ahnmc.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2350-2361 Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2350
Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma
Min Yao, Rong-Fei Fang, Qun Xie, Min Xu, Wen-Li Sai, Deng-Fu Yao
Min Yao, Deng-Fu Yao, Department of Immunology, Medical School of Nantong University and Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
Rong-Fei Fang, Department of Gastroenterology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
Qun Xie, Department of Infectious Diseases, Haian People’s Hospital, Haian 226600, Jiangsu Province, China
Min Xu, Wen-Li Sai, Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
Author contributions: Yao M, Fang RF, Xie Q and Xu M contributed equally to this work and wrote draft of the paper; Xie Q, Xu M and Sai WL performed literature search for the manuscript; Sai WL and Yao DF revised the manuscript and edited all drafts of the paper; and all authors approved the final version of the manuscript.
Supported byNational Natural Science Foundation of China, No. 81673241 and No. 31872738; and Nantong Infectious Disease Alliance Fund, No. 202308001.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deng-Fu Yao, MD, PhD, Professor, Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, No. 20 West Temple Road, Nantong 226001, Jiangsu Province, China. yaodf@ahnmc.com
Received: February 22, 2024 Revised: April 2, 2024 Accepted: April 24, 2024 Published online: June 15, 2024 Processing time: 113 Days and 24 Hours
Abstract
The prevention and early diagnosis of liver cancer remains a global medical challenge. During the malignant transformation of hepatocytes, a variety of oncogenic cellular signalling molecules, such as novel high mobility group-Box 3, angiopoietin-2, Golgi protein 73, glypican-3, Wnt3a (a signalling molecule in the Wnt/β-catenin pathway), and secretory clusterin, can be expressed and secreted into the blood. These signalling molecules are derived from different signalling pathways and may not only participate in the malignant transformation of hepatocytes but also become early diagnostic indicators of hepatocarcinogenesis or specific targeted molecules for hepatocellular carcinoma therapy. This article reviews recent progress in the study of several signalling molecules as sensitive biomarkers for monitoring hepatocarcinogenesis.
Core Tip: The early monitoring or diagnosis of hepatocellular carcinoma (HCC) are still medical challenge, and identifying novel biomarkers with high sensitivity and specificity for HCC are urgently needed. Recent progress in several oncogenic cellular signalling molecules that derived from different signalling pathways were reviewed, such as novel high mobility group-Box 3, angiopoietin-2, Golgi protein 73, glypican-3, Wnt3a (a signalling molecule in the Wnt/β-catenin pathway), and secretory clusterin. They might not only participate in the malignant transformation of hepatocytes but also become early diagnostic indicators of hepatocarcinogenesis or specific targeted molecules for HCC therapy.
